Skip to main content
. 2024 Mar 7;67(1):e24. doi: 10.1192/j.eurpsy.2024.19

Table 2.

Treatment choices; weighted data (n = 611)

CE Europe (n = 279) Southern (n = 92) Northern (n = 92) Western (n = 148) Total (n = 611)
Pharmacotherapy
   Any antidepressant 89 (82–94) 92 (82–96) 58 (41–73) 77 (66–85) 82 (76–86)
Particular antidepressants
   Sertraline 63 (53–72) 80 (69–88) 49 (33–65) 61 (49–71) 64 (58–70)
   Venlafaxine 17 (11–25) 11 (5–23) 5 (3–8) 7 (3–12) 10 (7–14)
   Other SSRI 36 (27–46) 21 (12–33) 9 (6–13) 15 (9–22) 21 (17–25)
   Mirtazapine 9 (6–13) 17 (9–31) 17 (9–31) 14 (8–23) 14 (10–19)
   Trazodone 13 (8–20) 13 (7–22) 5 (3–9) 11 (7–16) 11 (9–15)
   Tricyclic antidepressants 1 (0–5) 1 (0–4) 1 (0–3) 3 (0–13) 2 (1–6)
Other drugs
   Benzodiazepines 33 (24–42) 23 (14–37) 11 (4–27) 9 (7–11) 18 (15–21)
   Anticonvulsants 3 (1–7) 3 (0–18) 0 (0–0) 0 (0–0) 1 (1–3)
   Antipsychotics 4 (2–7) 2 (1–6) 0 (0–0) 3 (1–13) 3 (1–6)
Psychotherapy
   Trauma-focused CBT 46 (36–56) 43 (32–55) 63 (42–80) 57 (46–67) 52 (45–58)
   Psychoeducation about trauma 31 (23–41) 24 (15–37) 40 (23–61) 41 (30–52) 35 (29–42)
   Cognitive behavioral therapy 42 (32–52) 30 (19–45) 13 (9–17) 18 (12–28) 26 (21–32)
   Cognitive processing therapy 33 (24–42) 23 (14–37) 11 (4–27) 9 (7–11) 18 (15–21)
   EMDR 9 (6–13) 17 (9–31) 17 (9–31) 14 (8–23) 14 (10–19)
   Prolonged exposure 13 (8–20) 13 (7–22) 5 (3–9) 11 (7–16) 11 (9–15)
   Psychodynamic psychotherapy 9 (5–17) 7 (3–17) 5 (3–10) 11 (6–19) 9 (6–14)
   Narrative exposure therapy 1 (0–5) 1 (0–4) 1 (0–3) 3 (0–13) 2 (1–6)
   Systemic therapy 4 (1–11) 0 (0–0) 0 (0–2) 0 (0–0) 1 (0–3)
   Other trauma-focused psychotherapy 3 (1–7) 3 (0–18) 0 (0–0) 0 (0–0) 1 (1–3)
   Other therapy 2 (1–3) 1 (0–4) 1 (0–3) 12 (6–22) 7 (4–12)

Abbreviations: CBT, cognitive behavioral therapy; CE, central and eastern; EMDR, eye movement desensitization and reprocessing.

Note: Data are presented as weighted percentage (95% confidence interval).